AGA Gastroenterology Republishes POWER Framework June 19, 2026 — Multidisciplinary Obesity-Care Model Integrating GLP-1 Medications, Endoscopic Therapies, and Bariatric Surgery as Complementary Tools
The American Gastroenterological Association published a commentary in its journal Gastroenterology on June 19, 2026 revisiting and updating the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. The revised framework reflects developments since 2017: the arrival of highly effective GLP-1 weight-loss medications (semaglutide, tirzepatide, retatrutide), expanded endoscopic therapies (Fractyl Revita duodenal mucosal resurfacing, intragastric balloons, endoscopic sleeve gastroplasty), and broader use of bariatric surgery. The framework formalizes a multidisciplinary care model that treats medications, endoscopic procedures, and surgery as complementary rather than competing — and addresses the post-GLP-1 weight-regain question by positioning endoscopic 'gut reset' procedures as part of the standard treatment arsenal. The commentary frames the next era of obesity care as combining GLP-1 medications with personalized procedures and surgery for greater results.